

Certificate of Analysis

PKC α , active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-484, 14-484-K, 14-484M

Parent Lot # 33245U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant human full length PKC α expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA agarose. Purity 99% by SDS-PAGE and Coomassie Blue staining. MW = 78kDa.

Specific Activity (Parent lot# 33245U): 3597U/mg, where one unit of PKC alpha activity is defined as 1nmol phosphate incorporated into 0.1mg/ml histone H1 per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.203mg/ml of enzyme in 20mM Tris/HCl pH7.5, 5% glycerol, 10mM benzamidine, 1mM PMSF, 1mM EGTA, 1mM EDTA, 0.02% Triton X-100, 0.1% 2-mercaptoethanol. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.67–5.08ng of this lot of enzyme phosphorylated 0.1mg/ml histone H1 in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as PKC α with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

- 1. 10 x Reaction Buffer:** 200mM HEPES/NaOH pH7.4.
- 2. CaCl₂:** Make up a 1mM stock in dH₂O. Add 2.5µl of stock per assay point.
- 3. Histone H1:** Use at a final assay concentration of 0.1mg/ml. Make up a 1mg/ml stock in 20mM MOPS pH 7.0. Add 2.5µl of stock per assay point.
- 4. 10 x Lipid Activator:** 0.3% Triton X-100, 1mg/ml phosphatidylserine, 0.1mg/ml diacylglycerol). Use 2.5µl of stock per assay point.
- 5. PKCα, active:** Dilute with 20mM HEPES/NaOH pH7.4, 0.03% Triton X-100. Use 0.67–5.08ng per assay point.
- 6. [γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 2.5µl of 10 x reaction buffer per assay to wells.
2. Add 2.5µl of **histone H1**.
3. Add 2.5µl of PKC lipid activator.
4. Add 2.5µl of 1mM CaCl₂
5. Add **2.5µl (0.67–5.08ng) PKCα, active**.
6. Add 2.5µl of dH₂O.
7. Add 10µl of diluted [γ-³³P]ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5µl of 3% phosphoric acid.
10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
12. Wash filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

PKC α Sequence Information

<u>Protein</u>	human PKC α
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	M8 of the recombinant protein is equivalent to M1 of human PKC α
<u>Accession number</u>	GenBank X52479

Recombinant PKC α amino acid sequence:

```

1  MHHHHHMHMAD  VFPGNDSTAS  QDVANRFARK  GALRQKNVHE  VKDHKFIARF  FKQPTFCSHC
61  TDFIWGFGKQ   GFQCQVCCFV  VHKRCHFEVT  FSCPGADKGP  DTDDPRSKHK  FKIH TYGSPT
121 FCDHCGSLLY  GLIHQGMKCD  TCDMNVHKQC  VINVPSLCGM  DHTEKRGRYI  LKAEVADEKL
181 HVTVRDAKNL  IPMDPNGLSD  PYVKLKLIPD  PKNESKQKTK  TIRSTLN PQW  NESFTFKLKP
241 SDKDRRLSVE  IWDWDRTRRN  DFMGSLSFV   SELMKMPASG  WYKLLNQEEG  EYYNVIPIEG
301 DEEGNMELRQ  KFEKAKLGPA  GNKVISPSED  RKQPSNNLDR  VKLTDFNFLM  VLGKGSFGKV
361 MLADRKGTEE  LYAIKILKGD  VVIQDDVEEC  TMVEKRVLAL  LDKPPFLTQL  HSCFQTVDR L
421 YFVMEYVNGG  DLMYHIQQVG  KFKEPQAVFY  AAEISIGLFF  LHKRGIYRD   LKLDNVM LDS
481 EGHKIADFG   MCKEHMMDGV  TTRTFCGTPD  YIAPEIIAYQ  PYGKSVDWWA  YGVLLYEMLA
541 GQPPFDGEDE  DELFQSIMEH  NVSYPKSLSK  EAVSICKGLM  TKHPAKRLGC  GPEGERDVRE
601 HAFFRRIDWE  KLENREIQPP  FKPKVCGKGA  ENFDKFFTRG  QPVLTPDQL   VIANIDQSD F
661 EGFSYVNPQF  VHPILQSAV
  
```

Recombinant PKC α nucleotide sequence:

```

1  atgcatcatc  accatcacca  tatggctgac  gttttcccgg  gcaacgactc  cacggcgtct
61  caggacgtgg  ccaaccgctt  cgccccaaa  ggggcgctga  ggccagaaga  cgtgcacgag
121  gtgaaggacc  acaaatcat  cgcgcgctt  ttcaagcagc  ccaccttctg  cagccactgc
181  accgacttca  tctgggggtt  tgggaaaca  ggcttccagt  gccaaagttg  ctgttttgtg
241  gtccacaaga  ggtgcatga  atttgttact  ttttcttgtc  cgggtgcgga  taagggaccc
301  gacactgatg  accccaggag  caagcacaag  ttcaaaatcc  acacttacgg  aagccccacc
361  ttctgcatc  actgtgggtc  actgctctat  ggacttatcc  atcaagggat  gaaatgtgac
421  acctgcatg  tgaacgttca  caagcaatg  gtcataatg  tccccagcct  ctgcccgaatg
481  gatcacata  agaagagggg  gcgatttac  ctaaaggctg  aggttgctga  tgaaaagctc
541  catgtcacag  tagagatgc  aaaaaatcta  atccctatgg  atccaaacgg  gctttcagat
601  ccttatgtga  actgaaact  tattcctgat  cccaagaatg  aaagcaagca  aaaaacaaa
661  accatccgct  ccacactaaa  tccgcagtgg  aatgagtcct  ttacattcaa  attgaaacct
721  tcagacaaag  accgacgact  gtctgtagaa  atctgggact  gggatcgaac  aacaaggaat
781  gacttcatgg  gatccctttc  ctttggagtt  tcggagctga  tgaagatgcc  ggccagtggg
841  tggtaacaag  tgcttaacca  agaagaaggt  gagtactaca  acgtacccat  tccggaaggg
901  gacgaggaag  gaaacatgga  actcaggcag  aaattcgaga  aagccaaact  tggccctgct
961  ggcaacaaag  tcatcagtc  ctctgaagac  aggaaacaac  cttccaaca  ccttgaccga
1021  gtgaaactca  cggacttcaa  tttcctcatg  gtgttgggaa  aggggagttt  tggaaagggtg
1081  atgcttgccg  acaggaagg  cacagaaga  ctgtatgcaa  tcaaaatcct  gaagaaggat
1141  gtggtgattc  aggatgatga  cgtggagtgc  accatggtag  aaaagcgagt  cttggccctg
1201  cttgacaaac  ccccgttctt  gacgcagctg  cactcctgct  tccagacagt  ggatcggctg
1261  tacttctgca  tggaatatgt  caacggtggg  gacctcatgt  accacattca  gcaagtagga
1321  aaatttaagg  aaccacaagc  agtattctat  gcggcagaga  tttccatcgg  attgttcttt
1381  cttcataaaa  gaggaatcat  ttatagggat  ctgaagttag  ataacgtcat  gttggattca
1441  gaaggacata  tcaaaattgc  tgactttggg  atgtgcaagg  aacacatgat  ggatggagtc
1501  acgaccagga  ctttctgtgg  gactccagat  tatatcgccc  cagagataat  cgcttatcag
1561  ccgtatggaa  aatctgtgga  ctggtgggcc  tatggcgtcc  tgttgatga  aatgcttgcc
1621  gggcagcctc  catttgatgg  tgaagatgaa  gacgagctat  ttcagtctat  catggagcac
  
```

Certificate of Analysis

```
1681 aacgtttcct atccaaaatc cttgtccaag gaggctgttt ctatctgcaa aggactgatg
1741 accaaacacc cagccaagcg gctgggctgt gggcctgagg gggagagggga cgtgagagag
1801 catgccttct tccggaggat cgactgggaa aaactggaga acagggagat ccagccacca
1861 ttcaagccca aagtgtgtgg caaaggagca gagaactttg acaagttctt cacacgagga
1921 cagcccgtct taacaccacc tgatcagctg gttattgcta acatagacca gtctgatttt
1981 gaagggttct cgtatgtcaa cccccagttt gtgcacccca tcttacagag tgcagtatga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.